Mesoblast (ASX:MSB) Notes Receivable: A$0.00 Mil (As of Dec. 2025)


ASX:MSB Mesoblast Ltd ASX:MSB
46 GF Score
Price A$1.89
! 4 Warning Signs
View Full Analysis

What is Mesoblast Notes Receivable?

Mesoblast ASX:MSB -9.38% 46 Notes Receivable is A$0.00 Mil as of Dec. 2025. GuruFocus rates ASX:MSB with a GF Score™ of 46/100. The stock has 4 warning signs investors should review.

Mesoblast's Notes Receivable for the quarter that ended in Dec. 2025 was A$0.00 Mil.

Mesoblast Notes Receivable Historical Data

* Premium members only.

The historical data trend for Mesoblast's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mesoblast Notes Receivable Chart

Mesoblast Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Mesoblast Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ASX:MSB
46GF Score
Mesoblast Ltd ASX:MSB
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mesoblast Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of A$0.00 Mil mean?
Mesoblast (ASX:MSB) has a Notes Receivable of A$0.00 Mil as of Dec. 2025. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Mesoblast and its competitors.
Is Mesoblast's Notes Receivable too high?
Mesoblast's current Notes Receivable is A$0.00 Mil. Overall, Mesoblast has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Mesoblast's Notes Receivable compare to VRTX and REGN?
Mesoblast's Notes Receivable of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Mesoblast and its competitors. Mesoblast's current Notes Receivable is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mesoblast stock overvalued right now?
Mesoblast (ASX:MSB) has a current Notes Receivable of A$0.00 Mil. The current Notes Receivable is A$0.00 Mil. Mesoblast's overall GF Score™ is 46/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Mesoblast (ASX:MSB), the current Notes Receivable is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Mesoblast Business Description

Address 55 Collins Street, Level 38, Melbourne, VIC, AUS, 3000
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
46GF Score

Get the complete analysis for ASX:MSB

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$1.89
Price